In a report released yesterday, Andrew Cooper from Raymond James maintained a Buy rating on Avantor (AVTR – Research Report), with a price target of $26.00. The company’s shares closed yesterday at $20.17.
Cooper covers the Healthcare sector, focusing on stocks such as Exact Sciences, Haemonetics, and Veracyte. According to TipRanks, Cooper has an average return of -24.8% and a 19.57% success rate on recommended stocks.
In addition to Raymond James, Avantor also received a Buy from Citigroup’s Patrick B Donnelly in a report issued yesterday. However, on the same day, Credit Suisse maintained a Hold rating on Avantor (NYSE: AVTR).
See the top stocks recommended by analysts >>
The company has a one-year high of $42.48 and a one-year low of $17.91. Currently, Avantor has an average volume of 6.84M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
Read More on AVTR:
